PHARMACY

Pamida offers incentive program to regular pharmacy customers

BY Alaric DeArment

OMAHA, Neb. A retailer in Nebraska is rewarding customers for filling their prescriptions at its pharmacies by offering discounts on purchases.

Pamida announced the introduction of its “Fill More. Save More.” program Tuesday, saying it would give price breaks to customers.

“We encourage those who are not currently Pamida pharmacy customers to take advantage of this program,” Pamida vice president for pharmacy Jeff Walsh said. “Transferring prescriptions can be done quickly and easily right at the pharmacy counter.”

The program does not require membership and uses punch cards, which are available at the 125 Pamida stores that operate pharmacies.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Walgreens reports increase in sales for September

BY Jenna Duncan

DEERFIELD, Ill. Walgreens today reported that its sales for the month of September totaled $4.85 billion, up 10 percent from the same month last year. Calendar year-to-date, sales totaled $44.35 billion reflecting an increase of 9.9 percent from last year’s total of $40.36 billion.

The company also said that comparable-store sales, covering stores open for at least one year, increased by 4.7 percent. Front-end comp-store sales increased 1.3 percent, the company reported. Walgreens credited front-end sales numbers to strong beauty and consumables sales.

According to Walgreens, pharmacy sales comprised 67.2 percent of total sales for September. September pharmacy sales increased 11.2 percent, while comparable pharmacy sales increased 6.5 percent. Comparable pharmacy sales were negatively impacted by 2.4 percentage points due to generic drug introductions in the last 12 months. Total prescriptions filled at comparable stores increased 3.5 percent.

In September, Walgreens cut the ribbon on 36 stores, including three relocations, and acquired three stores.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves new treatment for HIV

BY Alaric DeArment

PRINCETON, N.J. The Food and Drug Administration has approved a new combination therapy for HIV from Bristol-Myers Squibb, Bristol announced Wednesday.

The treatment, which combines 300 mg of the drug Reyataz (atazanavir sulfate) with 100 mg of ritonavir, is for people with untreated HIV, also known as treatment-naive patients.

“Boosted Reyataz provides healthcare professionals a newly approved, once-daily dosing option as part of combination therapy for patients naive to HIV therapy,” said Dr. Elliott Sigal, Bristol’s executive vice president, chief scientific officer and president for research and development.

The treatment is based on the 48-week CASTLE study, which demonstrated that the once-daily combined therapy was similar in efficacy to the twice-daily combination of lopinavir and ritonavir.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES